ANGELINI PHARMA

Angelin is a private, international group - leader in Healthcare and Well-being. His effort is helping patients, physicians and caregivers in the fight against diseases. Angelini gives constant and foremost attention to the areas of **Pain and Inflammation, Neuroscience and Infectious Diseases**.

Founded in Italy at the beginning of the 20th century, Angelini has activities in **18 countries** in the pharmaceutical industry, employs over **3,000 people** and has a turnover of over **870 million euros**.

Angelin is an integrated pharmaceutical company with extensive and well-recognised **Research and Development** programmes, in addition to world-class **production facilities** and international marketing activities of key compounds and leading drugs in many sectors. Strategic partnerships with international companies complete and expand the geographical areas where Angelini operates.

In Italy and abroad, Angelini has a strong historical experience in the field of over-the-counter (OTC) medications.

Over the years, the **Research and Development** teams at Angelini have identified several important molecules such as trazodone and benzydamine, and are currently involved in innovative research projects in the areas of **mental health and chronic neuropathic pain**. Angelini has a particular commitment to the research of novel drugs for the paediatric population.

The research at Angelini embraces public-private partnerships with recognised academic institutions and centres of global importance. The Scientific Network and Partnerships both contribute to create innovative products marketed by Angelini.

Angelini’s **production facilities** in Ancona (Finished Products), Aprilia (Raw Materials) and Casella are at the forefront of technologies, industry standards and environmental protection, thanks to the use and integration of renewable sources.

Angelini has offices in Italy, Spain, Portugal, Austria, Poland, Czech Republic, Slovakia, Hungary, Germany, Romania, Bulgaria, Slovenia, Croatia, Greece, Turkey, Russia, USA and Pakistan.

In line with its **international strategies**, Angelini has developed pathways for development in countries with high growth potential, with both targeted acquisitions and enhancement of existing structures.

Moreover, important strategic alliances with leading pharmaceutical groups with a global footprint allow the distribution of Angelini products worldwide. To name a few, these include **Trittico** (trazodone, antidepressant), **Latuda** (lurasidone hydrochloride, antipsychotic), **Tantum** (benzydamine, anti-inflammatory), **Aulin** (nimesulide, anti-inflammatory analgesic), Vellofent (fentanyl, analgesic) and **Xydalba** (dalbavancin).

In the last 10 years, the percentage sales outside Italy has grown constantly, reaching about 50% of total pharma sales today.
ANGELINI AT A GLANCE

- 3,000 employees
- 18 countries in which Angelini is present
- Over 50 countries in which products are marketed
- Over 50 commercial partners
- 3 production plants in Italy

Contact:
Pharma HQ External Communications
Fabio Pieroni +39 06 91045443  f.pieroni@angelini.it
Felicia Ridola +39 06 91045444  f.ridola@angelini.it